查詢結果分析
來源資料
相關文獻
- 慢性C型肝炎之全口服小分子藥物治療
- 由實證醫學來探討慢性C型肝炎的治療--給臨床醫師關於長效型干擾素的治療準則
- 對以往干擾素治療不反應或復發之慢性C型肝炎患者的治療考量
- 慢性B型肝炎合併慢性C型肝炎治療之新契機
- 慢性C型肝炎治療的新時代
- Falsely Low Hemoglobin A1c Values in Diabetic Patients Receiving Peginterferon-alpha and Ribavirin for Chronic Hepatitis C
- 慢性C型肝炎患者肝臟移植後病毒復發感染之狀況與治療
- 慢性C型肝炎治療的新展望
- 如何妥善因應及減少慢性C型肝炎病患在接受干擾素合併ribavirin治療所產生之副作用
- The Genotypes of Hepatitis C Virus In Patients With Chronic Hepatitis C Virus Infection in Southern Taiwan
頁籤選單縮合
題名 | 慢性C型肝炎之全口服小分子藥物治療=Direct-Acting Antiviral Agents for Chronic Hepatitis C |
---|---|
作者姓名(中文) | 楊勝舜; 高嘉宏; | 書刊名 | 臺灣醫學 |
卷期 | 21:2 2017.03[民106.03] |
頁次 | 頁125-134 |
分類號 | 415.5332 |
關鍵詞 | 慢性C型肝炎; 長效型干擾素; 雷巴威林; 全口服小分子藥物; 持久病毒學反應; 基因型; 基因亞型; 抗藥相關替換; Chronic hepatitis C; Pegylated interferon; Ribavirin; Direct-acting antiviral agents; Sustained virologic response; Genotype; Subtype; Resistance-associated substitution; |
語文 | 中文(Chinese) |
中文摘要 | C型肝炎是全球主要的肝臟疾病。臺灣C肝抗體陽性盛行率在一般人口約2%-5%,病毒基因型分佈以1b型最多,2a型次之。C型肝炎仍無疫苗可供預防,長效型聚乙二醇干擾素合併口服抗病毒藥物雷巴威林24或48週曾經是C型肝炎之標準治療,雖有不錯療效但有禁忌症及顯著副作用。近來全口服小分子藥物與干擾素/雷巴威林合併,甚至免除干擾素,對難治的第一型病患接受8至24週不等療程的治療有90%以上的持久病毒學反應。本文將回顧C型肝炎病毒學、流行病學、致病機轉與抗病毒藥物作用機制,介紹全口服小分子藥物及當前國內外主流肝病醫學會對C型肝炎治療的建議。 |
英文摘要 | Chronic hepatitis C (CHC) is one of the major liver diseases worldwide. The prevalence of antibodies to hepatitis C virus (anti-HCV) is 2-5% in the general population in Taiwan, with HCV genotype 1b and 2a as the most common subtypes. HCV vaccine is not yet available and pegylated interferon alfa plus ribavirin (PR) for 24 to 48 weeks had been the standard of care for CHC with good effectiveness. However, the ineligibility and substantial adverse effects prevent many patients from PR therapy. The recent introduction of direct acting antivirals (DAA) in combination with PR or interferon-free DAA for 8-24 weeks bears the sustained virologic response (SVR) rate of > 90%. In this article, the virology, epidemiology, pathogenesis of HCV infection and modes of action for DAA regimens will be reviewed. In addition, the treatment recommendations for CHC in several professional societies will be introduced. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。